Delhi High Court Orders Review Of Indian Decision Against Ranbaxy Drug Price
This article was originally published in PharmAsia News
Executive Summary
India's Delhi High Court has ordered the government to reconsider a decision fixing the price of Ranbaxy's antibiotic Roscillin (ampicillin sodium). The National Pharmaceutical Pricing Authority had declined to review its decision, saying Ranbaxy must first bring its price for the drug into line, and then file for a review. The court ordered the Ministry of Chemicals and Fertilizers to consider the Ranbaxy request within four weeks. The ultimate decision is expected to have the force of a judicial ruling. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.